Some aspects of the background symptomatic treatment of cognitive impairment of various severity types
https://doi.org/10.21518/2079-701X-2013-12-50-54
Abstract
This literature review outlines the role of glutamatergic disturbances in the pathogenesis of cognitive disorders. There is data on the effectiveness of the glutamate NMDA-receptors antagonist - memantine - in patients with various dementias: Alzheimer's disease, dementia with Lewy bodies, vascular and mixed dementia. The authors share own positive experience with the drug Akatinol Memantine at various dementias. Options for administration of the drug in patients with mild cognitive impairment are discussed; results of a multicenter regional study are provided. The efficacy and safety of Akatinol Memantine as a medication to improve cognitive function is highlighted.
References
1. Андросова Л.В., Селезнева Н.Д. Акатинол мемантин при болезни Альцгеймера: клинико-иммунологические корреляции. Ж. невролог. и психиатр., 2000;100(9):36-38.
2. Дамулин И.В. Новая нейропротективная и терапевтическая стратегия при деменциях: антагонист NMDA-рецепторов Акатинол Мемантин. Русск. мед. журн., 2001;9(25):1178-1182.
3. Захаров В.В., Яхно Н.Н. Синдром умеренных когнитивных нарушений в пожилом возрасте – диагностика и лечение. РМЖ, 2004;10:573-576.
4. Успенская О.В., Яхно Н.Н. Влияние мемантина на когнитивные функции пациентов с амнестическим вариантом синдрома умеренных когнитивных расстройств (клинико-психологическое и нейрохимическое исследование). Неврологический журнал, 2009;14(3):49-54.
5. Яхно Н.Н., Преображенская И.С., Захаров В.В., Мхитарян Э.А. Эффективность Акатинола Мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал, 2010;15(2):52-58.
6. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine: results of a phase II double-blind study. Pharmacopsychiatry,1998;21:144-146.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association. 1994:143-147.
8. Arvanov VL, Chou HC, Chen RC, Tsai MC. Pre- and post-synaptic actions of memantine at cholinergic central synapse of achatina fulica. Comp. Biochem. Physiol., 1994;107:305-311.
9. Chan SL, Lu C, Mattson MP. Modification of cysteine proteases and AMPA receptor subunits by the lipid peroxidation product 4-hydroxynonenal: Impact on neuronal apoptosis and necrosis. Neurobiol. Aging., 2000;21(1S):17.
10. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci. Lett., 1998;86:109-113.
11. Danysz W, Parsons CG, Mobius HJ, et al. Neuroprotective and synptomatological action of memantine relevant for Alzheimer’s disease – A unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res., 2000;2:85-97.
12. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol. Rev., 1999;51:7-62.
13. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittel-Forschung., 1991;41:773-780.
14. Dubois B, Slachevsky A, Litvan I, Pillon BA. frontal assessment battery at bedside. Neurology, 2000;55:1621-1626.
15. Erkinjuntti T, Hachinski VC. Rethinking vascular dementia. Cerebrovasc. Dis., 1993;3:3-23.
16. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 1975;12:189-198.
17. Foy CJ, Passmore AP, Vahidassr MD, et al. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. Q. J. Med. 1999. 92:39-45.
18. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiat. 1999. 66:137-147.
19. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br. J. Psychiatry. 1982. 140. 566-572.
20. Kornhuber J, Wiltfang J. The role glutamate in dementia. J. Neural. Transm. 1998. 53 (suppl.). 277-287.
21. Law A, Gauthier S, Quirion R. Say NO to Alzheimer’s disease: the putative links between nitric oxide and dementia of the Alzheimer’s type. Brain Res. Rev. 2001. 35. 73-96.
22. Mao J. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res. Rev. 1999. 30. 289-304.
23. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging. Amer. J. Neuroradiol. 2001. 22. 1813-1824.
24. Matsuoka Y, Picciano MJ, Malester BT, et al. Inflammatory responses and oxidative stresses in PS/APP mice. Neurobiol. Aging. 2000. 21(1S). 18.
25. Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources, Inc., 1988.
26. IG McKeith, D Galasko, K Kosaka, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996. 47. 1113-1124.
27. McKhann G, Drachman D, Folstein M. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984. 34. 939-944.
28. Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer’s dementia. Pharmacopsychiatr. 1995. 28. 113-124.
29. Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioral evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Zeitsch. Gerontopsychol Psychiatr. 1993. 6. 103-117.
30. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998. 11. 9. 523-569.
31. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacol. 1999. 38. 735-767.
32. Reisberg B, Windscheif U, Ferris S, et al. Memantine in moderately severe to severe Alzheimer’s disease: Results of placebo-controlled 6-month trial. Neurobiol. Aging. 2000. 21. 275.
33. GC Roman, TK Tatemichi, T Erkinjuntti, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993. 43. 250-260.
34. Ruter E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D-Scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatr. 2000. 33. 103-108.
35. Sahin K, Stoeffler A, Furtuna P, et al. Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol. Aging. 2000. 21. 27.
36. Wilcock G, Stoeffler A, Sahin K, Moebius HJ. Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur. Neuropsychopharm. 2000. 10, 3. 360.
37. Winblad B, Wimo A, Mobius HJ, et al. Severe dementia: a common condition entailing high costs at individual and societal levels. Int. J. Geriatr. Psychiatr. 1999. 14. 911-914.
38. Wolf-Klein GR, Silverstone FA, Levy AP, et al. Screening for Alzheimer's disease by clock drawing. J. of American Geriatrics Society., 1989. 37. 730-734.
Review
For citations:
Preobrazhenskaya IS. Some aspects of the background symptomatic treatment of cognitive impairment of various severity types. Meditsinskiy sovet = Medical Council. 2013;(12):50-54. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-50-54
Views:
465
Email this article 